Markets
markets

Snap jumps after revealing plans to lay off ~16% of its workforce, new guidance sees Q1 revenue up ~12% year on year

Snap jumped as much as 10% in premarket trading on Wednesday after the social media company announced that it may cut about 1,000 roles, or roughly 16% of its full-time employees, in an attempt to improve profitability.

In an SEC filling that followed its Investor Update presentation on Wednesday, Snap also added that it will be closing more than 300 open roles. As a result of the job cuts and other measures, the company expects to save roughly $500 million in annualized expenses by the second half of 2026.

Through the latest moves, Snap is “pivoting towards profitable growth,” per CEO Evan Spiegel, doubling down on its more than 60% gross margin target for 2026. It also joins a growing list of tech companies cutting jobs citing AI, with Spiegel adding that “rapid advancements in artificial intelligence [will] enable our teams to reduce repetitive work, increase velocity, and better support our community, partners, and advertisers.”

In the same investor update event, Snap also updated parts of its Q1 financial outlook, including reduced guidance on its stock compensation and adjusted operating expenses. The company now expects revenue of approximately $1.529 billion, up 12% year over year and just above analyst expectations of $1.524 billion, as compiled by Bloomberg. Snap expects adjusted EBITDA to come in at $233 million, again ahead of Wall Streets current forecasts ($184 million).

More Markets

See all Markets
markets

Spectrum-owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its full-year revenue per user guidance.

“It'll be close either way in terms of whether we end up with net growth,” said Fischer.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.